CNTA Centessa Pharmaceuticals | $13.02
-1.0% | 8/15/2023 | Target Raised by | SVB Securities | - | Outperform -> Outperform | $6.00 -> $11.00 | Low | View details for SVB Securities rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 8/15/2023 |
CYTK Cytokinetics | $33.63
+1.8% | 8/15/2023 | Initiated by | SVB Securities | - | Outperform | $58.00 | Low | View details for SVB Securities rating of Cytokinetics (NASDAQ:CYTK) on 8/15/2023 |
DSGN Design Therapeutics | $3.50
+3.7% | 8/15/2023 | Downgraded by | SVB Securities | - | Outperform -> Market Perform | $6.00 | Low | View details for SVB Securities rating of Design Therapeutics (NASDAQ:DSGN) on 8/15/2023 |
RLAY Relay Therapeutics | $3.51
+1.3% | 8/8/2023 | Initiated by | SVB Securities | - | Outperform | | Low | View details for SVB Securities rating of Relay Therapeutics (NASDAQ:RLAY) on 8/8/2023 |
NUVL Nuvalent | $77.92
+2.1% | 8/8/2023 | Initiated by | SVB Securities | - | Market Perform | $42.00 | Low | View details for SVB Securities rating of Nuvalent (NASDAQ:NUVL) on 8/8/2023 |
IDYA IDEAYA Biosciences | $21.13
+0.5% | 8/8/2023 | Initiated by | SVB Securities | - | Outperform | $33.00 | Low | View details for SVB Securities rating of IDEAYA Biosciences (NASDAQ:IDYA) on 8/8/2023 |
EXEL Exelixis | $43.54
-1.2% | 8/8/2023 | Initiated by | SVB Securities | - | Market Perform | $18.00 | Low | View details for SVB Securities rating of Exelixis (NASDAQ:EXEL) on 8/8/2023 |
QTRX Quanterix | $6.73
+1.1% | 8/8/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $30.00 | Low | View details for SVB Securities rating of Quanterix (NASDAQ:QTRX) on 8/8/2023 |
NVCR NovoCure | $17.95
+0.8% | 8/4/2023 | Initiated by | SVB Securities | - | Outperform | $51.00 | Low | View details for SVB Securities rating of NovoCure (NASDAQ:NVCR) on 8/4/2023 |
BLTE Belite Bio | $58.26
+1.0% | 7/26/2023 | Initiated by | SVB Securities | - | Outperform | $25.00 | Low | View details for SVB Securities rating of Belite Bio (NASDAQ:BLTE) on 7/26/2023 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
NBIX Neurocrine Biosciences | $127.98
+1.8% | 7/24/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $115.00 -> $125.00 | Low | View details for SVB Securities rating of Neurocrine Biosciences (NASDAQ:NBIX) on 7/24/2023 |
CYRX CryoPort | $7.29
-2.3% | 7/13/2023 | Downgraded by | SVB Securities | - | Outperform -> Market Perform | $30.00 -> $10.00 | Low | View details for SVB Securities rating of CryoPort (NASDAQ:CYRX) on 7/13/2023 |
BMY Bristol Myers Squibb | $47.46
+2.5% | 7/10/2023 | Initiated by | SVB Securities | - | Market Perform | $66.00 | Low | View details for SVB Securities rating of Bristol Myers Squibb (NYSE:BMY) on 7/10/2023 |
MLTX MoonLake Immunotherapeutics | $46.69
-1.1% | 6/26/2023 | Target Raised by | SVB Securities | - | | $28.00 -> $56.00 | Low | View details for SVB Securities rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 6/26/2023 |
EHAB Enhabit | $7.86
-18.5% | 6/20/2023 | Initiated by | SVB Securities | - | Underperform | $10.00 | Low | View details for SVB Securities rating of Enhabit (NYSE:EHAB) on 6/20/2023 |
PEPG PepGen | $1.10
-1.4% | 6/14/2023 | Target Lowered by | SVB Securities | - | | $33.00 -> $28.00 | Low | View details for SVB Securities rating of PepGen (NASDAQ:PEPG) on 6/14/2023 |
UNH UnitedHealth Group | $325.03
+4.2% | 6/14/2023 | Target Lowered by | SVB Securities | - | | $625.00 -> $560.00 | Low | View details for SVB Securities rating of UnitedHealth Group (NYSE:UNH) on 6/14/2023 |
OCS Oculis | $18.96
-2.3% | 6/12/2023 | Initiated by | SVB Securities | - | Outperform | | Low | View details for SVB Securities rating of Oculis (NASDAQ:OCS) on 6/12/2023 |
CVAC CureVac | $5.42
-0.3% | 6/8/2023 | Initiated by | SVB Securities | - | Outperform | $13.00 | Low | View details for SVB Securities rating of CureVac (NASDAQ:CVAC) on 6/8/2023 |
CSTL Castle Biosciences | $20.35
-0.3% | 6/5/2023 | Target Lowered by | SVB Securities | - | | $50.00 -> $35.00 | Low | View details for SVB Securities rating of Castle Biosciences (NASDAQ:CSTL) on 6/5/2023 |
BPMC Blueprint Medicines | $128.32
+0.1% | 6/5/2023 | Downgraded by | SVB Securities | - | Market Perform -> Underperform | $48.00 -> $43.00 | Low | View details for SVB Securities rating of Blueprint Medicines (NASDAQ:BPMC) on 6/5/2023 |
ELEV Elevation Oncology | $0.37
+0.2% | 5/30/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $5.00 -> $8.00 | Low | View details for SVB Securities rating of Elevation Oncology (NASDAQ:ELEV) on 5/30/2023 |
UHS Universal Health Services | $189.08
+4.4% | 5/26/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $147.00 -> $170.00 | Low | View details for SVB Securities rating of Universal Health Services (NYSE:UHS) on 5/26/2023 |
A Agilent Technologies | $120.30
+2.2% | 5/24/2023 | Target Lowered by | SVB Securities | - | Outperform | $170.00 -> $145.00 | Low | View details for SVB Securities rating of Agilent Technologies (NYSE:A) on 5/24/2023 |
ARWR Arrowhead Pharmaceuticals | $16.12
+2.0% | 5/12/2023 | Downgraded by | SVB Securities | - | Outperform -> Market Perform | $40.00 | Low | View details for SVB Securities rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/12/2023 |
VIR Vir Biotechnology | $5.10
+1.1% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $43.00 -> $42.00 | Low | View details for SVB Securities rating of Vir Biotechnology (NASDAQ:VIR) on 5/5/2023 |
REGN Regeneron Pharmaceuticals | $536.94
+2.3% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $976.00 -> $895.00 | Low | View details for SVB Securities rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/5/2023 |
PRVA Privia Health Group | $22.54
-2.0% | 5/5/2023 | Target Raised by | SVB Securities | - | | $39.00 -> $40.00 | Low | View details for SVB Securities rating of Privia Health Group (NASDAQ:PRVA) on 5/5/2023 |
LNTH Lantheus | $79.63
-2.7% | 5/5/2023 | Target Raised by | SVB Securities | - | | $120.00 -> $127.00 | Low | View details for SVB Securities rating of Lantheus (NASDAQ:LNTH) on 5/5/2023 |
AMED Amedisys | $96.26
-2.2% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $96.00 -> $81.00 | Low | View details for SVB Securities rating of Amedisys (NASDAQ:AMED) on 5/5/2023 |
ALHC Alignment Healthcare | $14.10
+0.7% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $24.00 -> $12.00 | Low | View details for SVB Securities rating of Alignment Healthcare (NASDAQ:ALHC) on 5/5/2023 |
AGIO Agios Pharmaceuticals | $34.34
+3.3% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $37.00 -> $34.00 | Low | View details for SVB Securities rating of Agios Pharmaceuticals (NASDAQ:AGIO) on 5/5/2023 |
ABCL AbCellera Biologics | $3.49
+1.6% | 5/5/2023 | Target Lowered by | SVB Securities | - | | $16.00 -> $15.00 | Low | View details for SVB Securities rating of AbCellera Biologics (NASDAQ:ABCL) on 5/5/2023 |
LLY Eli Lilly and Company | $778.42
-0.1% | 5/1/2023 | Target Raised by | SVB Securities | - | | $410.00 -> $458.00 | Low | View details for SVB Securities rating of Eli Lilly and Company (NYSE:LLY) on 5/1/2023 |
DHR Danaher | $201.11
+1.8% | 5/1/2023 | Initiated by | SVB Securities | - | Outperform | $300.00 | Low | View details for SVB Securities rating of Danaher (NYSE:DHR) on 5/1/2023 |
HUM Humana | $251.57
+2.9% | 4/27/2023 | Target Lowered by | SVB Securities | - | | $640.00 -> $600.00 | Low | View details for SVB Securities rating of Humana (NYSE:HUM) on 4/27/2023 |
ALVR AlloVir | $2.67
+1.9% | 4/26/2023 | Target Raised by | SVB Securities | - | | $368.00 -> $437.00 | Low | View details for SVB Securities rating of AlloVir (NASDAQ:ALVR) on 4/26/2023 |
PRTA Prothena | $6.25
+3.0% | 4/24/2023 | Initiated by | SVB Securities | - | Outperform | $80.00 | Low | View details for SVB Securities rating of Prothena (NASDAQ:PRTA) on 4/24/2023 |
MRUS Merus | $52.70
+0.2% | 4/17/2023 | Target Raised by | SVB Securities | - | Outperform | $35.00 -> $48.00 | Low | View details for SVB Securities rating of Merus (NASDAQ:MRUS) on 4/17/2023 |
FDMT 4D Molecular Therapeutics | $4.16
+12.2% | 4/13/2023 | Target Lowered by | SVB Securities | - | Market Perform | $14.00 -> $13.00 | Low | View details for SVB Securities rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 4/13/2023 |
Banks aren’t ready for this altcoin—are you? (Ad) I've never been more confident about a DeFi opportunity.
This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now. Discover our #1 crypto for the red-hot crypto market right now! |
BBIO BridgeBio Pharma | $42.83
-0.8% | 4/13/2023 | Target Raised by | SVB Securities | - | Outperform | $25.00 -> $27.00 | Low | View details for SVB Securities rating of BridgeBio Pharma (NASDAQ:BBIO) on 4/13/2023 |
ARWR Arrowhead Pharmaceuticals | $16.12
+2.0% | 4/12/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $21.00 -> $35.00 | Low | View details for SVB Securities rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 4/12/2023 |
CORT Corcept Therapeutics | $70.15
-4.4% | 4/11/2023 | Initiated by | SVB Securities | - | Market Perform | $25.00 | Low | View details for SVB Securities rating of Corcept Therapeutics (NASDAQ:CORT) on 4/11/2023 |
IPHA Innate Pharma | $1.83
+0.8% | 4/10/2023 | Target Raised by | SVB Securities | - | | $9.00 -> $10.00 | Low | View details for SVB Securities rating of Innate Pharma (NASDAQ:IPHA) on 4/10/2023 |
ACLX Arcellx | $64.95
-1.4% | 3/30/2023 | Target Raised by | SVB Securities | - | | $35.00 -> $39.00 | Low | View details for SVB Securities rating of Arcellx (NASDAQ:ACLX) on 3/30/2023 |
REGN Regeneron Pharmaceuticals | $536.94
+2.3% | 3/27/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $834.00 -> $976.00 | Low | View details for SVB Securities rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 3/27/2023 |
INCY Incyte | $68.66
+0.8% | 3/24/2023 | Upgraded by | SVB Securities | - | Underperform -> Market Perform | $61.00 | Low | View details for SVB Securities rating of Incyte (NASDAQ:INCY) on 3/24/2023 |
PTCT PTC Therapeutics | $48.61
-0.5% | 3/17/2023 | Initiated by | SVB Securities | - | Market Perform | $48.00 | Low | View details for SVB Securities rating of PTC Therapeutics (NASDAQ:PTCT) on 3/17/2023 |
CNTA Centessa Pharmaceuticals | $13.02
-1.0% | 3/17/2023 | Initiated by | SVB Securities | - | Outperform | $6.00 | Low | View details for SVB Securities rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 3/17/2023 |
HALO Halozyme Therapeutics | $52.89
+1.7% | 3/16/2023 | Downgraded by | SVB Securities | - | Outperform -> Market Perform | $42.00 | Low | View details for SVB Securities rating of Halozyme Therapeutics (NASDAQ:HALO) on 3/16/2023 |
FULC Fulcrum Therapeutics | $6.79
-1.4% | 3/10/2023 | Target Lowered by | SVB Securities | - | | $18.00 -> $10.00 | Low | View details for SVB Securities rating of Fulcrum Therapeutics (NASDAQ:FULC) on 3/10/2023 |
ARGX argenex | $546.76
-0.8% | 3/3/2023 | Target Raised by | SVB Securities | - | | $430.00 -> $435.00 | Low | View details for SVB Securities rating of argenex (NASDAQ:ARGX) on 3/3/2023 |
AHCO AdaptHealth | $9.42
-0.2% | 3/1/2023 | Target Lowered by | SVB Securities | - | | $30.00 -> $23.00 | Low | View details for SVB Securities rating of AdaptHealth (NASDAQ:AHCO) on 3/1/2023 |
MDRX Veradigm | $4.70
+2.2% | 3/1/2023 | Target Lowered by | SVB Securities | - | | $24.00 -> $17.00 | Low | View details for SVB Securities rating of Veradigm (NASDAQ:MDRX) on 3/1/2023 |
GPCR Structure Therapeutics | $20.68
-0.3% | 2/28/2023 | Initiated by | SVB Securities | - | Outperform | $33.00 | Low | View details for SVB Securities rating of Structure Therapeutics (NASDAQ:GPCR) on 2/28/2023 |
IRON Disc Medicine | $51.42
-2.9% | 2/28/2023 | Initiated by | SVB Securities | - | Outperform | $36.00 | Low | View details for SVB Securities rating of Disc Medicine (NASDAQ:IRON) on 2/28/2023 |
NKTR Nektar Therapeutics | $24.52
-5.1% | 2/24/2023 | Target Lowered by | SVB Securities | - | | $75.00 -> $45.00 | N/A | View details for SVB Securities rating of Nektar Therapeutics (NASDAQ:NKTR) on 2/24/2023 |
BPMC Blueprint Medicines | $128.32
+0.1% | 2/24/2023 | Target Lowered by | SVB Securities | - | | $45.00 -> $38.00 | Low | View details for SVB Securities rating of Blueprint Medicines (NASDAQ:BPMC) on 2/24/2023 |
MRNA Moderna | $28.86
+4.6% | 2/24/2023 | Downgraded by | SVB Securities | - | Market Perform -> Underperform | $111.00 -> $93.00 | Low | View details for SVB Securities rating of Moderna (NASDAQ:MRNA) on 2/24/2023 |
IONS Ionis Pharmaceuticals | $39.98
+1.2% | 2/23/2023 | Target Lowered by | SVB Securities | - | | $34.00 -> $27.00 | Low | View details for SVB Securities rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 2/23/2023 |
TDOC Teladoc Health | $8.54
-2.0% | 2/23/2023 | Upgraded by | SVB Securities | - | Market Perform -> Outperform | $34.00 | Low | View details for SVB Securities rating of Teladoc Health (NYSE:TDOC) on 2/23/2023 |
ABBV AbbVie | $189.75
+2.2% | 2/10/2023 | Upgraded by | SVB Securities | - | Underperform -> Market Perform | $135.00 -> $153.00 | Low | View details for SVB Securities rating of AbbVie (NYSE:ABBV) on 2/10/2023 |
VRTX Vertex Pharmaceuticals | $452.62
+1.7% | 2/8/2023 | Target Lowered by | SVB Securities | - | | $374.00 -> $365.00 | Low | View details for SVB Securities rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 2/8/2023 |
CI Cigna Group | $334.74
+1.3% | 2/8/2023 | Target Lowered by | SVB Securities | - | | $335.00 -> $309.00 | Low | View details for SVB Securities rating of Cigna Group (NYSE:CI) on 2/8/2023 |
META Meta Platforms | $719.88
-2.5% | 2/2/2023 | Target Raised by | SVB Securities | - | Outperform | $220.00 -> $255.00 | Low | View details for SVB Securities rating of Meta Platforms (NASDAQ:META) on 2/2/2023 |
AMGN Amgen | $290.84
+4.2% | 2/2/2023 | Target Lowered by | SVB Securities | - | | $282.00 -> $267.00 | Low | View details for SVB Securities rating of Amgen (NASDAQ:AMGN) on 2/2/2023 |
DNLI Denali Therapeutics | $13.94
-0.4% | 1/30/2023 | Initiated by | SVB Securities | - | Outperform | $50.00 | Low | View details for SVB Securities rating of Denali Therapeutics (NASDAQ:DNLI) on 1/30/2023 |
BHVN Biohaven | $13.99
-0.9% | 1/24/2023 | Initiated by | SVB Securities | - | Outperform | $24.00 | Low | View details for SVB Securities rating of Biohaven (NYSE:BHVN) on 1/24/2023 |
